

Mitchell Gold M.D.

Venture Partner Frazier Life Sciences

Mitch is currently a venture partner at Frazier Life Sciences. A Healthcare investment company focused on company creation as well as public investing. Prior to FLS Mitch was most recently Alpine Immune Sciences Co-Founder, CEO, and the Executive

Chairman of Alpine's Board of Directors since the company was founded

in January 2015 until its sale to Vertex Pharmaceuticals in May of 2024 for \$4.9 billion. Prior to co-founding Alpine Immune Sciences, Mitch

was the Chairman and Founder of Alpine Biosciences, a privately held

biotech company dedicated to developing the next generation of cancer

and orphan disease treatments. Alpine Biosciences was sold to Cascadian Therapeutics in 2014 which was subsequently acquired by SGEN.

Both Alpine Immune Sciences and Alpine Biosciences received their seed funding from Alpine Bioventures. A venture capital firm Mitch founded in 2012 focused on new company creation.

Earlier in his career Mitch was the CEO and Chairman of Dendreon Corporation, where he

and his team developed the world's first cell-based therapy to be approved by the

FDA. Dendreon ushered in an entirely new era in cancer treatments with

the FDA approval of PROVENGE® (sipuleucel-T), in April 2010.

Mitch holds an M.D. from Rush Medical College in Chicago and did his Urology Residency at the University of Washington Medical Center and holds a B.S. in Biology from the University of Wisconsin-Madison